Breast Cancer Research and Treatment **58**: 303-304, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 58

Aihara T 137
Altomonte M 19
Alvarez E 141
Ammerman C 193
Antalis TM 255
Arndt D 71
Asselain B 151

Baak JPA 163
Bernehim J 65
Binh NC 281
Blau R 205
Bomstein Y 65
Borg A 295
Brackett DJ 131
Broët P 151
Buesa JM 141
Burroughs M 31
Buzdar A 157

Cattarossi I 19
Cattelan A 19
Ceccarelli C 107
Cetto GL 123
Chieco P 107
Corral N 141
Couch FJ 25
Cowan D 31
Cummings MC 255

de la Rochefordière A 151
De Rycke Y 151
Deng G 213
DeWille JW 57
Diel P 87
Dinh NV 281
Dotzlaw H 219
Dressler LG 31
Duc NB 281

Egeblad M 41
Esteban E 141
Estrada E 141
Ethier SP 193

Fahr A 71
Fernández JL 141
Fichtner I 71
Flanagan L 193
Fonsatti E 19
Fourquet A 151
Fujimoto S 11
Fujimoto T 11
Fujiwara Y 137

Gajalakshmi CK 115
Gamberini M 107
Gazder P 205
Geradts J 31
Gigliotto AP 57
Grunt TW 171

Hakama M 115
Hanas JS 131
Havighurst TC 281
Heppner GH 183
Herbert RA 241
Hines SJ 1
Hollingsworth AB 131
Hoshi N 11
Howell A 157
Huang A 219
Huber H 171

Ingram DM 267
Ishioka C 11

Jäättelä M 41
Jernström HCB 295
Jett EA 131
Johannsson OT 295

Kaufman Z 65
Kim YS 213
Klein A 65
Klein E 65
Krystal GW 1

Lacave AJ 141
Lamaj E 19
Larsen SS 41
Lee D 157
Leonhart AM 163
Lerner MR 131
Leygue E 219
Lightfoot LA 131
Lindor NM 25
Litz JS 1
Liu W 25
Liverant S 65
Loman N 295
Love RR 281
Lower EE 205
Luckie SM 255
Lykkesfeldt AE 41

Mai M 25
Maio M 19
Mark PJ 267
Marrano D 107
McGuckin MA 255
Meijer CJLM 163
Micciolo R 123
Michna H 87
Millikan RC 31
Minchin RF 267
Mohla S 183
Molino A 123
Mommers ECM 163
Monden M 137
Moreau T 151
Muñiz I 141
Murphy LC 219

Newman B 31
Ney E 241
Nortilli R 123

Offterdinger M 171
Olsson H 295
Ooka M 137

Pääkö P 287
Palacio I 141
Pavanel F 123
Pelosi G 123
Piana S 107
Pileri S 107

Pouillart P 151

Rao GN 241
Ratajczak T 267
Robertson JFR 157
Roche PC 25
Rosen J 183

Sagawa T 11
Sakita I 137
Sakuragi N 11
Salomon D 183
Santini D 107
Schneider SM 171
Scholl SM 151
Schwartz DI 25
Shanta V 115
Shapira Y 65
Shpitz B 65
Smith DI 25
Smith G 183
Smith ML 99
Smolnikar K 87
Stahl DL 205
Sugawara T 11

Taffurelli M 107
Talvensaari-Mattila A 287
Tamaki Y 137
Teppke AD 71
Tsao SW 227
Turazza M 123
Turpeenniemi-Hajanen T 287

van Diest PJ 163
Van Weelden K 193
Vieitez JM 141
von Euler M 157

Walsh MD 255
Walsh-Vockley C 25
Ward BK 267
Watson PH 219
Welsh J 193
Wolman SR 183
Wong YC 227

Xie B 227

Yamada H 11
Yamashita Y 11

Zehavi T 65
Zeisig R 71
Zemer R 65
Zimlichman S 65

Breast Cancer Research and Treatment **58**: 305-308, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 58

adhesion molecule sICAM-1
elevated in serum with early breast cancer vs. benign lesions 19-23
anastrozole
static disease equivalent to objective response for survival benefit 157-162
androgens
in regulation of $TGF\beta_1$ and TGFα in mammary carcinogenesis 227-239
antiestrogen resistance
no change in ErbB family receptors 41-56
antiestrogens
inhibition by ICI 182,780 overcome by heregulin 41-56
apoptosis
different changes in progression of well vs. poorly differentiated lesions 163-169
greater induction by ICI 182,780 than tamoxifen in MCF-7 cells 87-97
in normal mammary involution, induced by local factors 57-63
axillary nodes
detection of micrometastases by mammaglobin B RT-PCR in 14/45 histologically negative nodes 137-140

Bcl-2
greater reduction by ICI 182,780 than tamoxifen in MCF-7 cells 87-97
bone marrow aspirates
presence of epithelial cells over time not prognostic 123-130
BRCA1
incidence in Japanese ovarian cancer patients, and breast cancer screening 11-17
BRCA1 and BRCA2
status does not affect reproductive risk factors 295-301

C/EBPs (CCAAT/enhancer binding proteins)
and mammary involution induced by local rather than systemic hormonal factors 57-63
carcinogenesis
androgen stimulation of $TGF\beta_1$ and TGFα during 227-239
cell lines
SUM-159PT cells for xenograft model of estrogen-independent breast cancer 193-204
chemotherapy
CEF (epirubicin) superior to CNF (mitoxantrone) combination 141-150
improved antitumor pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes 71-80
short but not long term benefit of primary vs. adjuvant chemotherapy 151-156
cisplatin
sensitization by Mdm2 overexpression as by p53 mutation 99-105
contralateral breast cancer
analysis of survival vs. unilateral breast cancer 115-122

DCIS (ductal carcinoma in situ)
different changes in proliferation/apoptosis ratio in well vs. poorly differentiated lesion progression 163-169
DCIS (ductal carcinoma in situ)
telomerase activity in 8/9 samples 65-69
diagnosis
circulating sICAM-1 elevated with early breast cancer vs. benign lesions 19-23
DNA repair
reduced by Mdm2 overexpression as by p53 mutation 99-105

EGF family growth factors
response enhanced by stem cell factor and receptor Kit 1-10
endocrine therapy
oophorectomy/tamoxifen treatment in Vietnamese women — side effects 281-286
static disease equivalent to objective response for survival benefit (anastrozole or megace) 157-162
epirubicin
CEF (epirubicin) superior to CNF (mitoxantrone) combination 141-150
epithelial mucin
heterogeneity of MUC1 expression in 14 human breast cancer cell lines 255-266

ErbB family receptors
no change on selection for antiestrogen resistance 41-56
control by cross-talk of nuclear receptor family and protein kinase signaling 171-181
ErbB-2
internal vs. external domains (by IHC) and tumor aggressiveness 107-114
erbB-2 gene copy number
improved "competitively differential" PCR method 213-217
erbB-2 gene copy number
improved "competitively differential" PCR method 213-217
estrogen receptor
ER status vs. levels of ER-associated immunophilins Cyp40 and FKBP52 267-280
ER variants and IHC ER results using N vs. C terminal antibodies 219-225
more likely with previous estrogen therapy (HRT, OC) 205-211
estrogen therapy
ER+ tumors more common after 205-211

family history
and occurrence of contralateral breast cancer 115-122

gene amplification
improved "competitively differential" PCR method 213-217
genetic testing
BRCA1 incidence in Japanese ovarian cancer patients, and breast cancer screening 11-17
genetics
p73 mutations not significant in sporadic or hereditary breast cancer 25-29
GnRH agonists
leuprolide equivalent to oophorectomy in preventing rat DMBA mammary tumors 131-136

Her-2/*neu*
see ErbB-2
hereditary breast cancer
reproductive risk factors not associated with BRCA1 and 2 status 295-301
heregulin
overcomes inhibition by antiestrogen ICI 182,780 41-56
response enhanced by stem cell factor and receptor Kit 1-10
hexadecylphosphocholine
improved antitumor pharmacokinetics in sterically stabilized liposomes 71-80
hormone replacement therapy
ER+ tumors more common after 205-211

ICI 182,780
vs. tamoxifen in reducing Bcl-2, inducing apoptosis in MCF-7 cells 87-97
immunohistochemistry
ER variants and IHC ER results using N vs. C terminal antibodies 219-225
immunophilins
ER-associated cyclophilin 40 and FKBP52 levels vs. ERα status 267-280

Kit (stem cell factor receptor)
enhancing response to EGF family ligands 1-10

lactation cycle
C/EBPs and involution induced by local rather than systemic hormonal factors 57-63
leuprolide
equivalent to oophorectomy in preventing rat DMBA mammary tumors 131-136
liposomes
improved antitumor pharmacokinetics of sterically stabilized hexadecylphosphocholine formulations 71-80

mammaglobin B
RT-PCR to detect micrometastases in axillary nodes 137-140
mammary development
delay by retinoids associated with delayed tumor onset in *neu* transgenic model 241-254
mammary involution
and C/EBPs induced by local rather than systemic hormonal factors 57-63
matrix metalloproteinases
MMP-2 association with recurrence and metastasis 287-293
MCF-7 human breast cancer cells
ICI 182,780 vs. tamoxifen in inducing apoptosis 87-97
non change in ErbB family receptors on selection for antiestrogen resistance 41-56
MCF10AT xenograft model for neoplasia
report of a workshop 183-186

Mdm2
overexpression, like p53 mutation, reduces DNA repair and sensitizes to cisplatin 99-105
megestrol acetate
static disease equivalent to objective response for survival benefit 157-162
metastasis
association with MMP-2 positivity 287-293
related to internal vs. external ErbB-2 domain detection by IHC 107-114
micrometastases
detection by mammaglobin B RT-PCR in 14/45 histologically positive nodes 137-140
presence of epithelial cells in marrow over time not prognostic 123-130
mitoxantrone
CEF (epirubicin) superior to CNF (mitoxantrone) combination 141-150
MUC1
heterogeneity of expression in 14 human breast cancer cell lines, vs. tumorigenicity 255-266
mutations
in p73 (p53 homolog) not significant in sporadic or hereditary breast cancer 25-29

neoadjuvant chemotherapy
short but not long term benefit of primary vs. adjuvant chemotherapy 151-156
neu-MMTV transgenic mice
delay in mammary development and tumor onset by retinoids 241-254
nuclear receptor family
cross-talk in regulation of RAR and ErbB receptors 171-181

oophorectomy
with tamoxifen in treatment of Vietnamese women — side effects 281-286
ovarian cancer
BRCA1 incidence in Japanese ovarian cancer patients, and breast cancer screening 11-17

p73
mutations not significant in sporadic or hereditary breast cancer 25-29
paraffin blocks
UNC SPORE policy guidelines for research utilization 31-39
pathology
UNC SPORE policy guidelines for research use of paraffin blocks 31-39
PCR (polymerase chain reaction)
improved "competitively differential" PCR method for erbB-2 gene amplification assay 213-217
preneoplasia
MCF10AT xenograft model — report of a workshop 183-186
prevention
leuprolide equivalent to oophorectomy in preventing rat DMBA mammary tumors 131-136
primary chemotherapy
short but not long term benefit of primary vs. adjuvant chemotherapy 151-156
prognostic factors
presence of epithelial cells in marrow over time not prognostic 123-130
metalloproteinase MMP-2 287-293
proliferation
different changes in progression of well vs. poorly differentiated lesions 163-169

quality control
UNC SPORE policy guidelines for research use of paraffin blocks 31-39

retinoic acid receptors
control by cross-talk of nuclear receptor family and protein kinase signaling 171-181
retinoids
4HPR and arotinoid Ro 40-8757 — delay of mammary tumors in MMTV-*neu* transgenic mice 241-254
risk factors
reproductive factors not associated with BRCA1 and 2 status 295-301

serum markers
soluble ICAM-1 elevated with early breast cancer vs. benign lesions 19-23
signal transduction
stem cell factor, receptor enhance response to EGF family ligands 1-10
stem cell factor
enhancing response to EGF family ligands 1-10
steroid receptor family
cross-talk with protein kinases in regulation of RAR and ErbB receptors 171-181
SUM159-PT cells
for xenograft model of estrogen-independent breast cancer 193-204

tamoxifen
vs. ICI-182,780 in reducing Bcl-2, inducing apoptosis in MCF-7 cells 87-97
with oophorectomy in treatment of Vietnamese women — side effects 281-286
tamoxifen resistance
no change in ErbB family receptors 41-56
telomerase
activity in 8/9 DCIS as in 10/11 invasive tumors 65-69
testosterone
in regulation of $TGF\beta_1$ and TGFα in mammary carcinogenesis 227-239
$TGF\beta_1$
and TGFα regulation by androgens in mammary carcinogenesis 227-239
tumor banks
UNC SPORE policy guidelines for research use of paraffin blocks 31-39
tumorigenesis
different changes in proliferation/apoptosis ratio in well vs. poorly differentiated lesion progression 163-169
MCF10AT xenograft model for neoplasia — report of a workshop 183-186
telomerase activity in DCIS as well as IDC specimens 65-69
xenograft model for preneoplasia
MCF10AT — report of a workshop 183-186
ZM 182,780
see ICI 182,780